Prospects for antiviral ribozymes and deoxyribozymes

Reviews in Medical Virology

Volumn 14, Issue 1, 2004, Pages 47-64

  Peracchi, Alessio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; DEOXYRIBOZYME; ENZYME VARIANT; HAMMERHEAD RIBOZYME; HEPTAZYME; INTERFERON; LIPOSOME; MESSENGER RNA; RECOMBINANT ENZYME; RIBOZYME; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ENGINEERING; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME MODIFICATION; ENZYME STABILITY; ENZYME STRUCTURE; GENE REPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN TARGETING; REVIEW; RNA DEGRADATION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTISENSE ELEMENTS (GENETICS); ANTIVIRAL AGENTS; BASE SEQUENCE; DNA, CATALYTIC; DRUG DESIGN; GENE THERAPY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RNA, CATALYTIC; RNA, VIRAL;

EID: 1642458402     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.415     Document Type: Review

References (168)

1. Cech TR. Ribozymes and their medical implications. JAMA 1988; 260: 3030-3034.
2. Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990; 247: 1222-1225.
3. James HA, Gibson I. The therapeutic potential of ribozymes. Blood 1998; 91: 371-392.
4. Rossi JJ. The application of ribozymes to HIV infection. Curr Opin Mol Ther 1999; 1: 316-322.
5. Lustig B, Jeang KT. Biological applications of hammerhead ribozymes as anti-viral molecules. Curr Med Chem 2001; 8: 1181-1187.
6. Puerta-Fernandez E, Romero-Lopez C, Barroso-delJesus A, Berzal-Herranz A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol Rev 2003; 27: 75-97.
7. Khachigian LM. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J Clin Invest 2000; 106: 1189-1195.
8. Cairns MJ, Saravolac EG, Sun LQ. Catalytic DNA: a novel tool for gene suppression. Curr Drug Targets 2002; 3: 269-279.
9. Zhou C, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn EB. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994; 149: 33-39.
10. Lieber A, He CY, Polyak SJ, Gretch DR, Barr D, Kay MA. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70: 8782-8791.
11. Yu M, Ojwang J, Yamada O, et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 6340-6344.
12. zu Putlitz J, Yu Q, Burke JM, Wands JR. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J Virol 1999; 73: 5381-5387.
13. Trang P, Kilani A, Lee J, et al. RNase P ribozymes for the studies and treatment of human cytomegalovirus infections. J Clin Virol 2002; 25 Suppl 2: S63-S74.
14. Lewin AS, Hauswirth WW. Ribozyme gene therapy: applications for molecular medicine. Trends Mol Med 2001; 7: 221-228.
15. Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature 2002; 418: 252-258.
16. Chen Y, McMicken HW. Intracellular production of DNA enzyme by a novel single-stranded DNA expression vector. Gene Ther 2003; 10: 1776-1780.
17. Dave RS, Pomerantz RJ. RNA interference: on the road to an alternate therapeutic strategy! Rev Med Virol 2003; 13: 373-385.
18. Scherr M, Morgan MA, Eder M. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem 2003; 10: 245-256.
19. Gitlin L, Andino R. Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol 2003; 77: 7159-7165.
20. Forster AC, Symons RH. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 1987; 49: 211-220.
21. Branch AD, Robertson HD. A replication cycle for viroids and other small infectious RNAs. Science 1984; 223: 450-455.
22. Symons RH. Self-cleavage of RNA in the replication of small pathogens of plants and animals. Trends Biochem Sci 1989; 14: 445-450.
23. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328: 596-600.
24. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334: 585-591.
25. Hammann C, Lilley DM. Folding and activity of the hammerhead ribozyme. Chembiochem 2002; 3: 690-700.
26. 2+ requirement: importance of stem-loop II. Chembiochem 2002; 3: 1066-1071.
27. 2+ concentration. Nucleic Acids Res 1999; 27: 2400-2407.
28. Pley HW, Flaherty KM, McKay DB. Three-dimensional structure of a hammerhead ribozyme. Nature 1994; 372: 68-74.
29. Scott WG, Finch JT, Klug A. The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage. Cell 1995; 81: 991-1002.
30. Scott WG, Murray JB, Arnold JRP, Stoddard BL, Klug A. Capturing the structure of a catalytic RNA intermediate: the hammerhead ribozyme. Science 1996; 274: 2065-2069.
31. McKay D. Structure and function of the hammerhead ribozyme: an unfinished story. RNA 1996; 2: 395-403.
32. Kore AR, Vaish NK, Kutzke U, Eckstein F. Sequence specificity of the hammerhead ribozyme revisited: the NHH rule. Nucleic Acids Res 1998; 26: 4116-4120.
33. Ludwig J, Blaschke M, Sproat BS. Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine15.1 to inosine15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17. Nucleic Acids Res 1998; 26: 2279-2285.
34. Curtis EA, Bartel DP. The hammerhead cleavage reaction in monovalent cations. RNA 2001; 7: 546-552.
35. O'Rear JL, Wang S, Feig AL, Beigelman L, Uhlenbeck OC, Herschlag D. Comparison of the hammerhead cleavage reactions stimulated by monovalent and divalent cations. RNA 2001; 7: 537-545.
36. Zhou JM, Zhou DM, Takagi Y, et al. Existence of efficient divalent metal ion-catalyzed and inefficient divalent metal ion-independent channels in reactions catalyzed by a hammerhead ribozyme. Nucleic Acids Res 2002; 30: 2374-2382.
37. Dahm SC, Uhlenbeck OC. Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 1991; 30: 9464-9469.
38. 2+ binding affinities to the hammerhead ribozyme and correlation with cleavage activity. Biochemistry 1998; 37: 18094-18101.
39. Wang S, Karbstein K, Peracchi A, Beigelman L, Herschlag D. Identification of the hammerhead ribozyme metal ion binding site responsible for rescue of the deleterious effect of a cleavage site phosphorothioate. Biochemistry 1999; 38: 14363-14378.
40. Li Y, Breaker R. Kinetics of RNA degradation by specific base catalysis of transesterification involving the 2′-hydroxyl group. J Am Chem Soc 1999; 121: 5364-5372.
41. Qiu L, Moreira A, Kaplan G, et al. Degradation of hammerhead ribozymes by human ribonucleases. Mol Gen Genet 1998; 258: 352-362.
42. Beigelman L, McSwiggen JA, Draper KG, et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 1995; 270: 25702-25708.
43. Burlina F, Favre A, Fourrey J-L. Chemical engineering of RNase resistant and catalytically active hammerhead ribozymes. Bioorg Med Chem 1997; 5: 1999-2010.
44. Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000; 106: 1197-1202.
45. Shimayama T, Nishikawa F, Nishikawa S, Taira K. Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages. Nucleic Acids Res 1993; 21: 2605-2611.
46. Heidenreich O, Xu X, Swiderski P, Rossi JJ, Nerenberg M. Correlation of activity with stability of chemically modified ribozymes in nuclei suspension. Antisense Nucleic Acid Drug Dev 1996; 6: 111-118.
47. Jarvis TC, Wincott FE, Alby LJ, et al. Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem 1996; 271: 29107-29112.
48. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 69-84.
49. Wahlestedt C, Salmi P, Good L, et al. Potent and non-toxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000; 97: 5633-5638.
50. Stein D, Foster E, Huang SB, Weller D, Summerton J. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997; 7: 151-157.
51. Heidenreich O, Pieken W, Eckstein F. Chemically modified RNA: approaches and applications. FASEB J 1993; 7: 90-96.
52. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 1991; 253: 314-317.
53. Flory CM, Pavco PA, Jarvis TC, et al. Nuclease-resistant hammerhead ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci USA 1996; 93: 754-758.
54. Parry TJ, Cushman C, Gallegos AM, et al. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999; 27: 2569-2577.
55. Narlikar GJ, Herschlag D. Mechanistic aspects of enzymatic catalysis: lessons from the comparison of RNA and protein enzymes. Annu Rev Biochem 1997; 66: 19-59.
56. Jaeger L. The new world of ribozymes. Curr Opin Struct Biol 1997; 7: 324-335.
57. Peracchi A, Karpeisky A, Maloney L, Beigelman L, Herschlag D. A core folding model for catalysis by the hammerhead ribozyme accounts for its extraordinary sensitivity to abasic mutations. Biochemistry 1998; 37: 14765-14775.
58. Peracchi A. Enzyme catalysis: removing chemically 'essential' residues by site-directed mutagenesis. Trends Biochem Sci 2001; 28: 497-503.
59. Murray JB, Scott WG. Does a single metal ion bridge the A-9 and scissile phosphate groups in the catalytically active hammerhead ribozyme structure? J Mol Biol 2000; 296: 33-41.
60. Blount KF, Grover NL, Mokler V, Beigelman L, Uhlenbeck OC. Steric interference modification of the hammerhead ribozyme. Chem Biol 2002; 9: 1009-1016.
61. Khvorova A, Lescoute A, Westhof E, Jayasena SD. Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nat Struct Biol 2003; 10: 708-712.
62. Peracchi A. Origins of the temperature dependence of hammerhead ribozyme catalysis. Nucleic Acids Res 1999; 27: 2875-2882.
63. Salmi P, Sproat BS, Ludwig J, et al. Dopamine D(2) receptor ribozyme inhibits quinpirole-induced stereotypy in rats. Eur J Pharmacol 2000; 388: R1-R2.
64. Mandava N, Blackburn P, Paul DB, et al. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2002; 43: 3338-3348.
65. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001; 6: 303-315.
66. Kitajima I, Hanyu N, Soejima Y, et al. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human T-cell leukemia virus type I Tat/Rex mRNA. J Biol Chem 1997; 272: 27099-27106.
67. Konopka K, Rossi JJ, Swiderski P, Slepushkin VA, Duzgunes N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta 1998; 1372: 55-68.
68. Sioud M, Sorensen DR. A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nature Biotechnol 1998; 16: 556-561.
69. Bramlage B, Luzi E, Eckstein F. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. Nucleic Acids Res 2000; 28: 4059-4067.
70. Gait M. Peptide-mediated cellular delivery of anti-sense oligonucleotides and their analogues. Cell Mol Life Sci 2003; 60: 844-853.
71. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 2001; 8: 1188-1196.
72. Merdan T, Kunath K, Fischer D, Kopecek J, Kissel T. Intracellular processing of poly(ethylene imine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments. Pharm Res 2002; 19: 140-146.
73. Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 2002; 9: 1700-1707.
74. Bertrand E, Castanotto D, Zhou C, et al. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 1997; 1: 75-88.
75. Lee NS, Bertrand E, Rossi J. mRNA localization signals can enhance the intracellular effectiveness of hammerhead ribozymes. RNA 1999; 5: 1200-1209.
76. Michienzi A, Cagnon L, Bahner I, Rossi JJ. Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci USA 2000; 97: 8955-8960.
77. Zelphati O, Szoka FC, Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996; 13: 1367-1372.
78. Bramlage B, Alefelder S, Marschall P, Eckstein F. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake. Nucleic Acids Res 1999; 27: 3159-3167.
79. Kato Y, Kuwabara T, Warashina M, Toda H, Taira K. Relationships between the activities in vitro and in vivo of various kinds of ribozyme and their intracellular localization in mammalian cells. J Biol Chem 2001; 276: 15378-15385.
80. Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. Cancer Gene Ther 2002; 9: 71-86.
81. Bramlage B, Luzi E, Eckstein F. Designing ribozymes for the inhibition of gene expression. Trends Biotechnol 1998; 16: 434-438.
82. Zhao JJ, Lemke G. Rules for ribozymes. Mol Cell Neurosci 1998; 11: 92-97.
83. Scherr M, Rossi JJ, Sczakiel G, Patzel V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res 2000; 28: 2455-2461.
84. Mercatanti A, Rainaldi G, Mariani L, Marangoni R, Citti L. A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes. J Comput Biol 2002; 9: 641-653.
85. Birikh KR, Berlin YA, Soreq H, Eckstein F. Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA 1997; 3: 429-437.
86. Scherr M, Reed M, Huang CF, Riggs AD, Rossi JJ. Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. Mol Ther 2000; 2: 26-38.
87. Mir AA, Lockett TJ, Hendry P. Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers. Nucleic Acids Res 2001; 29: 1906-1914.
88. Herschlag D. RNA chaperones and the RNA folding problem. J Biol Chem 1995; 270: 20871-20874.
89. Warashina M, Kuwabara T, Kato Y, Sano M, Taira K. RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA. Proc Natl Acad Sci USA 2001; 98: 5572-5577.
90. Steele D, Kertsburg A, Soukup GA. Engineered catalytic RNA and DNA: new biochemical tools for drug discovery and design. Am J Pharmacogenom 2003; 3: 131-144.
91. Soukup GA, Breaker RR. Design of allosteric hammerhead ribozymes activated by ligand-induced structure stabilization. Structure Fold Des 1999; 7: 783-791.
92. Wang DY, Lai BH, Sen D. A general strategy for effector-mediated control of RNA-cleaving ribozymes and DNA enzymes. J Mol Biol 2002; 318: 33-43.
93. Vaish NK, Dong F, Andrews L, et al. Monitoring post-translational modification of proteins with allosteric ribozymes. Nat Biotechnol 2002; 20: 810-815.
94. Peracchi A, Beigelman L, Usman N, Herschlag D. Rescue of abasic hammerhead ribozymes by exogenous addition of specific bases. Proc Natl Acad Sci USA 1996; 93: 11522-11527.
95. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci USA 1991; 88: 6921-6925.
96. Denman RB. Hairpin ribozyme specificity in vivo: a case of promiscuous cleavage. Biochem Biophys Res Commun 1999; 257: 356-360.
97. Werner M, Uhlenbeck OC. The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis. Nucleic Acids Res 1995; 23: 2092-2096.
98. Singh KK, Schluff P, Lehnert L, Krupp G. Design of hammerhead ribozymes to distinguish single base changes in substrate RNA. Antisense Nucleic Acid Drug Dev 1996; 6: 165-168.
99. Desjardins JP, Sproat BS, Beijer B, et al. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J Pharmacol Exp Ther 1996; 278: 1419-1427.
100. Sandberg JA, Sproul CD, Blanchard KS, et al. Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Acid Drug Dev 2000; 10: 153-162.
101. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol 1999; 181: 251-257.
102. Breaker RR. DNA enzymes. Nat Biotechnol 1997; 15: 427-431.
103. Sen D, Geyer CR. DNA enzymes. Curr Opin Chem Biol 1998; 2: 680-687.
104. Breaker RR. Making catalytic DNAs. Science 2000; 290: 2095-2096.
105. 2+-dependent RNA phosphoesterase activity. Chem Biol 1995; 2: 655-660.
106. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262-4266.
107. 2+ ion as a cofactor for a novel RNA-cleaving deoxyribozyme. Angew Chem Int Ed Engl 1996; 35: 2837-2841.
108. + ions. Evidence for the identity of 8-17 with the catalytic domain of the Mg5 deoxyribozyme. J Biol Chem 2000; 275: 11693-11697.
109. Li J, Zheng W, Kwon AH, Lu Y. In vitro selection and characterization of a highly efficient Zn(II)-dependent RNA-cleaving deoxyribozyme. Nucleic Acids Res 2000; 28: 481-488.
110. Geyer CR, Sen D. Evidence for the metal-cofactor independence of an RNA phosphodiester-cleaving DNA enzyme. Chem Biol 1997; 4: 579-593.
111. Feldman AR, Sen D. A new and efficient DNA enzyme for the sequence-specific cleavage of RNA. J Mol Biol 2001; 313: 283-294.
112. Liu Z, Mei SH, Brennan JD, Li Y. Assemblage of signaling DNA enzymes with intriguing metal-ion specificities and pH dependences. J Am Chem Soc 2003; 125: 7539-7545.
113. Sioud M, Leirdal M. Design of nuclease resistant protein kinase ca DNA enzymes with potential therapeutic application. J Mol Biol 2000; 296: 937-947.
114. Dass CR, Saravolac EG, Li Y, Sun LQ. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev 2002; 12: 289-299.
115. Warashina M, Kuwabara T, Nakamatsu Y, Taira K. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome. Chem Biol 1999; 6: 237-250.
116. Oketani M, Asahina Y, Wu CH, Wu GY. Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease. J Hepatol 1999; 31: 628-634.
117. Vester B, Lundberg LB, Sorensen MD, Babu BR, Douthwaite S, Wengel J. LNAzymes: incorporation of LNA-type monomers into DNAzymes markedly increases RNA cleavage. J Am Chem Soc 2002; 124: 13682-13683.
118. Zaborowska Z, Furste JP, Erdmann VA, Kurreck J. Sequence requirements in the catalytic core of the '10-23' DNA enzyme. J Biol Chem 2002; 277: 40617-40622.
119. Santoro SW, Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 1998; 37: 13330-13342.
120. Kurreck J, Bieber B, Jahnel R, Erdmann VA. Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem 2002; 277: 7099-7107.
121. Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S, Taira K. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res 1997; 25: 3074-3081.
122. Chakraborti S, Banerjea AC. Identification of cleavage sites in the HIV-1 TAR RNA by 10-23 and 8-17 catalytic motif containing DNA enzymes. Biomacromolecules 2003; 4: 568-571.
123. Sun LQ, Cairns MJ, Gerlach WL, Witherington C, Wang L, King A. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J Biol Chem 1999; 274: 17236-17241.
124. Toyoda T, Imamura Y, Takaku H, et al. Inhibition of influenza virus replication in cultured cells by RNA-cleaving DNA enzyme. FEBS Lett 2000; 481: 113-116.
125. Goila R, Banerjea AC. Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochem J 2001; 353: 701-708.
126. Santiago FS, Lowe HC, Kavurma MM, et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nature Med 1999; 5: 1264-1269.
127. Sorensen DR, Leirdal M, Iversen PO, Sioud M. Combination of endostatin and a protein kinase C-a DNA enzyme improves the survival of rats with malignant glioma. Neoplasia 2002; 4: 474-479.
128. Cieslak M, Szymanski J, Adamiak R, Cierniewski CS. Structural rearrangements of the '10-23' DNA-zyme to beta 3 integrin subunit mRNA induced by cations and their relations to the catalytic activity. J Biol Chem 2003; 278: 47987-47996.
129. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991; 65: 5531-5534.
130. Lo KM, Biasolo MA, Dehni G, Palu G, Haseltine WA. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 1992; 190: 176-183.
131. Ventura M, Wang P, Franck N, Saragosti S. Ribozyme targeting of HIV-1 LTR. Biochem Biophys Res Commun 1994; 203: 889-898.
132. Michienzi A, Prislei S, Bozzoni I. U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. Proc Natl Acad Sci USA 1996; 93: 7219-7224.
133. Kuwabara T, Warashina M, Nakayama A, Ohkawa J, Taira K. tRNAVal-heterodimeric maxizymes with high potential as gene-inactivating agents: simultaneous cleavage at two sites in HIV-1 Tat mRNA in cultured cells. Proc Natl Acad Sci USA 1999; 96: 1886-1891.
134. Giordano V, Jin DY, Rekosh D, Jeang KT. Intravirion targeting of a functional anti-human immunodeficiency virus ribozyme directed to pol. Virology 2000; 267: 174-184.
135. Habu Y, Miyano-Kurosaki N, Nagawa T, Matsumoto N, Takeuchi H, Takaku H. Inhibition of HIV-1 replication by an HIV-1 dependent ribozyme expression vector with the Cre/loxP (ON/OFF) system. Antivir Chem Chemother 2002; 13: 273-281.
136. Gennari F, Biasolo MA, Cancellotti E, et al. Additive and antagonist effects of therapeutic gene combinations for suppression of HIV-1 infection. Antiviral Res 2002; 55: 77-90.
137. Ramezani A, Ma XZ, Nazari R, Joshi S. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Front Biosci 2002; 7: a29-36.
138. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998; 9: 2407-2425.
139. + hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999; 10: 2255-2270.
140. Dash BC, Harikrishnan TA, Goila R, et al. Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated cell fusion. FEBS Lett 1998; 431: 395-399.
141. Zhang X, Iwatani Y, Shimayama T, et al. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry. Antisense Nucleic Acid Drug Dev 1998; 8: 441-450.
142. Zhang X, Xu Y, Ling H, Hattori T. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. FEBS Lett 1999; 458: 151-156.
143. Sriram B, Banerjea AC. In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression. Biochem J 2000; 352: 667-673.
144. Unwalla H, Banerjea AC. Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA. Biochem J 2001; 357: 147-155.
145. Unwalla H, Banerjea AC. Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression. Antiviral Res 2001; 51: 127-139.
146. Chakraborti S, Banerjea AC. Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates. Mol Ther 2003; 7: 817-826.
147. Flamm SL. Chronic hepatitis C virus infection. JAMA 2003; 289: 2413-2417.
148. Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5′ noncoding region of hepatitis C virus. Proc Natl Acad Sci USA 1992; 89: 4942-4946.
149. Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, Barber J. A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 1996; 3: 994-1001.
150. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 1998; 10: 163-171.
151. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 98: 2720-2728.
152. Macejak DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV polio-virus using synthetic stabilized ribozymes. Hepatology 2000; 31: 769-776.
153. Ribozyme Pharmaceuticals Inc. website. http://www.rpi.com/clin1.jsp. [10 September 2003].
154. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003; 99: 55-77.
155. Jarvis TC, Alby LJ, Beaudry AA, et al. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RNA 1996; 2: 419-428.
156. Wan MS, Fell PL, Akhtar S. Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev 1998; 8: 309-317.
157. Giannini CD, Roth WK, Piiper A, Zeuzem S. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture. Nucleic Acids Res 1999; 27: 2737-2744.
158. Pickford AS, Cogoni C. RNA-mediated gene silencing. Cell Mol Life Sci 2003; 60: 871-882.
159. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98: 9742-9747.
160. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
161. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003; 13: 1-7.
162. Kretschmer-Kazemi Far R, Sczakiel G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 2003; 31: 4417-4424.
163. Hough SR, Wiederholt KA, Burrier AC, Woolf TM, Taylor MF. Why RNAi makes sense. Nat Biotechnol 2003; 21: 731-732.
164. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003; 278: 7108-7118.
165. Grunweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003; 31: 3185-3193.
166. Al-Anouti F, Ananvoranich S. Comparative analysis of antisense RNA, double-stranded RNA, and delta ribozyme-mediated gene regulation in Toxoplasma gondii. Antisense Nucleic Acid Drug Dev 2002; 12: 275-281.
167. Sledz CA, Holko M, De Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-839.
168. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-1644.